On Apr 5, 2013, at 5:29 AM, Vassilis Virvilis <v.virvi...@biovista.com> wrote:
> Hello,
>
> We have updated to cxf-2.7.4 and our internal test suite had hit the 50000
> limit of cxf configuration for the woodstox xml parser. Furthermore woodstox
> in this release is a hard requirement so we can't get rid of it.
>
> So far we have found (after digging in the source) the following system
> property that does the trick
> System.setProperty("org.apache.cxf.stax.maxChildElements", "100000");
>
> We can live with this client side but not server side since the setting is
> global and affects the whole jvm, other servlets, other endpoints etc
>
> So I have two questions.
>
> 1) Server side: How I can configure the limits from the spring configuration.
> Is it possible to do it per endpoint? per servlet?
> 2) Client side: How I can configure the limits programmatically?
You should be able to set the same property as an endpoint property in the
spring config or a Bus property, etc..
I need to test a bit on the client side. Ideally, you could just set it on
the client's request context, but since this applies to the response, I'm not
100% sure it would get picked up. Worst case, you can do
ClientProxy.getClient(proxy).getEndpoint().put("org.ap….", 100000);
That said, this is good information. We're trying to find a good balance for
defaults that would provide some level of security, but also not affect too
many people. We might tune some of these settings a bit more.
Dan
>
> Before you suggest to use attachments read below:
>
> Why we don't use attachments?
> -----------------------------
>
> The burden of handling attachments and the loss of portability does not
> justify their use for the specific function which generally returns a small
> number of elements back but rarely it can exceeds the cxf imposed woodstox
> limits.
>
> Vassilis
>
>
> --
>
> __________________________________
>
> Vassilis Virvilis Ph.D.
> Head of IT
> Biovista Inc.
>
> US Offices
> 2421 Ivy Road
> Charlottesville, VA 22903
> USA
> T: +1.434.971.1141
> F: +1.434.971.1144
>
> European Offices
> 34 Rodopoleos Street
> Ellinikon, Athens 16777
> GREECE
> T: +30.210.9629848
> F: +30.210.9647606
>
> www.biovista.com
>
> Biovista is a privately held biotechnology company that finds novel uses for
> existing drugs, and profiles their side effects using their mechanism of
> action. Biovista develops its own pipeline of drugs in CNS, oncology,
> auto-immune and rare diseases. Biovista is collaborating with
> biopharmaceutical companies on indication expansion and de-risking of their
> portfolios and with the FDA on adverse event prediction.
>
>
--
Daniel Kulp
dk...@apache.org - http://dankulp.com/blog
Talend Community Coder - http://coders.talend.com
